Clinical Trial Detail

NCT ID NCT03025035
Title Pembrolizumab in Advanced BRCA-mutated Breast Cancer
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors Monica Mita
Indications

breast cancer

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.